Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval

Executive Summary

AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005

You may also be interested in...



Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data

FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said

Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data

FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said

Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo

Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7

Related Content

UsernamePublicRestriction

Register

PS041782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel